They didn’t say anything about Clone 3, which is why I’m concerned and openly questioning things.
If they are sending Clone 3 as well as all the rest of the mabs, that’s effectively a buyout bc it leaves ENZC with nothing. And I can’t see Charles selling off the whole damn company for $450 million.
Clearly the main concern right now is (1) what is ENZC left with after this deal closes and (2) where does ENZC go moving forward after the deal closes?
I think these are perfectly reasonable questions to ask at this point for anyone invested here.
If they are selling off everything EXCEPT Clone 3, then we are good, bc they would have all the funds needed to finally send Clone 3 through any clinical trials here or internationally.